Real-world evaluation of isavuconazole in children with cancer
We think that isavuconazole merits a place for treatment of invasive fungal infections in children. Isavuconazole was generally well tolerated with exposures in line with the pivotal trial. Lower-weight children required higher dosage per kg of bodyweight to achieve equivalent exposures to their older peers. Considerable inter/intra-patient variability supports the need for therapeutic drug monitoring.
Authors
- Eline W. Muilwijk (ORCID: https://orcid.org/0000-0003-2348-1233)
- Roger J. M. Brüggemann (ORCID: https://orcid.org/0000-0002-7618-725X)
- Caroline A. Lindemans (ORCID: https://orcid.org/0000-0002-3984-5620)
- Janine Nijhuis
- Tissing Wj
- A. P. J. Jansen
- T F W Wolfs
- Louis J Bont
- Laura G Y Rotte
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- Canisius-Wilhelmina Ziekenhuis (NL)
- Princess Máxima Center (NL)
- Wilhelmina Children's Hospital (NL)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1093/jac/dkaf485
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00